SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape

Abstract

Characterizing SARS-CoV-2 evolution in specific geographies may help predict the properties of variants coming from these regions. We mapped neutralization of a SARS-CoV-2 strain that evolved over 6 months from the ancestral virus in a person with advanced HIV disease. Infection was before the emergence of the Beta variant first identified in South Africa, and the Delta variant. We compared early and late evolved virus to the ancestral, Beta, Alpha, and Delta viruses and tested against convalescent plasma from ancestral, Beta, and Delta infections. Early virus was similar to ancestral, whereas late virus was similar to Beta, exhibiting vaccine escape and, despite pre-dating Delta, strong escape of Delta-elicited neutralization. This example is consistent with the notion that variants arising in immune-compromised hosts, including those with advanced HIV disease, may evolve immune escape of vaccines and enhanced escape of Delta immunity, with implications for vaccine breakthrough and reinfections. HIGHLIGHTS: A prolonged ancestral SARS-CoV-2 infection pre-dating the emergence of Beta and Delta resulted in evolution of a Beta-like serological phenotypeSerological phenotype includes strong escape from Delta infection elicited immunity, intermediate escape from ancestral virus immunity, and weak escape from Beta immunityEvolved virus showed substantial but incomplete escape from antibodies elicited by BNT162b2 vaccination.

Full text

Its licence does not allow us to show the full text. Read it at PubMed Central:

References 45

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41591-021-01377-8

2. 2.
   Evidence for antibody as a protective correlate for COVID-19 vaccines · 2021

   No notice
3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1056/nejmoa2102214

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1016/j.cell.2021.03.013

5. 5.
   Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera · 2021

   No notice
6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41591-021-01318-5

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41586-021-03398-2

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41586-021-03402-9

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41586-021-03471-w

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41591-021-01285-x

11. 11.
    Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera · 2021

    No notice
12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-021-03324-6

13. 13.
    Antibody evasion by the P.1 strain of SARS-CoV-2 · 2021

    No notice
14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1056/nejmc2114706

16. 16.
    SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion · 2021

    No notice
17. 17.
    Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum · 2021

    No notice
18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-020-2852-1

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.chom.2021.02.003

20. 20.
    Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies · 2021

    No notice
21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2021.03.028

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.chom.2021.03.005

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2021.03.029

24. 24.
    A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 · 2020

    No notice
25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.7554/elife.67397

26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1097/qai.0000000000000845

27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/373123a0

28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.7326/0003-4819-135-1-200107030-00005

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.3201/eid2710.211461

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.
    Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment · 2021

    Not checked
32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1056/nejmc2031364

33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.cell.2021.03.027

34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-021-03291-y

35. 35.
    Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants · 2021

    No notice
36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-021-03237-4

37. 37.
    A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. · 2022

    Not checked
38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1126/science.1097211

40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1126/science.288.5472.1789

Cited by papers we hold 3

• Prevalence of persistent SARS-CoV-2 in a large community surveillance study · 2024
  No notice
• Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages · 2022
  No notice
• Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses · 2022
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.